Press releases //

IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test

IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked  diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

(…)  » 

Press releases //

IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers

IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools.

(…)  » 

Press releases //

IntegraGen Reports Financial Results for 1st Half of 2018

IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.

Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57% vs. (…)  » 

Press releases //

The SeqOIA Cooperative Health Group selects IntegraGen as the operator of its sequencing platform as part of the France Genomic Medicine 2025 Plan

integragen

IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the Gustave Roussy Cancer Center, (…)  »